New Awakn study shows ketamine has potential to treat alcoholism
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) has released encouraging data from a Phase II trial of ketamine-assisted therapy for the treatment of alcohol use disorders.
The company bought the rights to the trial, which was led by Professor Celia Morgan, Head of Ketamine Assisted Therapy for Addiction at Awakn and Professor of Psychopharmacology at the University of Exeter in the UK.
“We found that low, controlled doses of ketamine combined with manual psychological therapy can significantly increase abstinence rates after treatment,” Professor Morgan said.
The double-blind, placebo-controlled trial included 96 patients with severe alcohol use disorders, who were divided into different groups. The researchers used ketamine in combination with a proprietary manual treatment protocol called “Kare”, and tested this combination against a placebo combined with regular alcohol education.
Ketamine plus exclusive treatment resulted in complete abstinence for 162 out of 180 days over the subsequent 6-month period, achieving an increase in abstinence from approximately 2% pre-trial to 86% post-trial. The results for alcohol relapse at 6 months showed that the group receiving ketamine plus Kare therapy had a risk of relapse that was 2.7 times lower than that of the placebo plus alcohol education group.
Delix Therapeutics Raises $30M in Convertible Note Funding and Will Enhance Its Drug Development Program
Therapeutic Delix announced on Monday that it has raised more than $30 million in convertible note financing.
According to Delix, these funds will strengthen the company’s ability to grow its drug development program, pipeline and platform for novel neuroplasticity-promoting therapies known as psychoplastogens. The company will also use these funds to expand its team and gain the flexibility to undertake additional strategic opportunities in 2022.
Mark Rus, CEO of Delix said “this latest fundraising represents the strength of investor interest, partnership and support for Delix’s approach to drug development.”
Delix has had a rocky year, having raised about $70 million in a Series A prior to this $30 million convertible note financing.
Field Trip Receives Patent Grant Notice for Proprietary Psychedelic Molecule
Health during a field trip (NASDAQ:FTRP) has received Notice of Allowance for a U.S. patent application covering FT-104, its flagship psychedelic drug candidate.
According to the company, FT-104 is a more soluble and stable derivative form of the psychedelic molecule 4-HO-DiPT.
Field Trip’s patent claims cover the composition of matter and the use and manufacture of a family of compounds, including FT-104. The Field Trip Notice of Acceptance received does not equate to a granted patent, but is in the final track of this process.
Dr. Nathan Bryson, Scientific Director of Field Trip said FT-104 offers notable improvements over a known class of psychedelics. 4-HO-DiPT, the compound on which FT-104 is based, was first synthesized in 1977 and described by legendary chemist Alexander Shulgin.
Cybin Obtains Approval in Canada to Conduct Ketamine Brain Imaging Study
A Canadian Institutional Review Board has approved Cybin (NYSE: CYBN) to advance a company-sponsored feasibility study using core flow to measure the psychedelic effect of ketamine on the cerebral cortex.
Kernel Flow is a non-invasive, helmet-style brain imaging device. Cybin will retain a proprietary interest in all innovations discovered or developed through its independent analysis of study results.
“By leveraging Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during, and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reports,” said Doug Drysdale, CEO of Cybin.
The company received a similar endorsement from the United States FDA in October 2021.
Wesana Health Obtains FDA Approval for Meeting to Discuss Psilocybin-CBD Combination Molecule
The FDA has granted approval to Wesana Health Holdings Inc. (OTCQB:WSNAF) for a pre-IND meeting to discuss the novel therapy and proprietary protocol of SANA-013 for the treatment of symptoms related to traumatic brain injury such as major depressive disorder.
A pre-IND (Investigational New Drug) meeting is a necessary step towards the green light for a clinical trial in humans.
By using psilocybin and cannabidiol, SANA-013 aims to improve neuroplasticity and neurogenesis while acting as an anti-neuroinflammatory in the treatment of migraine and other symptoms associated with traumatic brain injury.
Ketamine One shares moved to OTCQB
KetamineOne Capital Limited (OTCQB: KONEF) announced on Wednesday that its common stock has been successfully transferred from the OTC Pink Sheet open market to the OTCQB Venture market under the ticker symbol “KONEF”.
The OTCQB offers traders the opportunity to invest in companies in the entrepreneurial and development stage. OTCQB companies must also prove that financial reports are up-to-date and go through other verification processes.
FDA approves PharmaTher phase 2 trial for ALS ketamine treatment
PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM) announced on Wednesday that the US FDA has accepted an application to proceed with a Phase 2 clinical trial evaluating ketamine for the treatment of amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig’s disease name. .
“The Phase 2 clinical trial is a prospective, double-blind, randomized, multiple-escalating-dose controlled study of ketamine that will enroll a total of 36 participants with ALS in 3 sequential cohorts, with 12 participants in each cohort,” according to the press. Release.
Atai Obtains Investigational New Drug Clearance for Arketamine Program
Atai Life Sciences (NASDAQ:ATAI) announced that the FDA has granted Investigational New Drug (IND) clearance to conduct a clinical drug interaction study of PCN-101, or Arketamine.
“We see great promise in PCN-101 as a potentially fast-acting antidepressant with a more favorable safety and tolerability profile than S-ketamine, which may allow home use,” said Florian brand, CEO and co-founder of Atai Life Sciences. “With today’s IND clearance, we are excited to continue evaluating the therapeutic potential of PCN-101 in the United States”
The clinical study is an open-label, 2-cohort, fixed-sequence, drug-drug interaction study to evaluate the effects of CYP450 inhibition on the pharmacokinetics of PCN-101 in healthy adult subjects. Atai will use the results of this study in conjunction with clinical pharmacokinetic data to advance the development of PCN-101 in treatment-resistant depression.